异基因骨髓移植后复发的青少年粒单核细胞白血病经α干扰素成功治疗。

Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha.

作者信息

Ohta H, Kawai M, Sawada A, Tokimasa S, Fujisaki H, Matsuda Y, Osugi Y, Okada S, Hara J

机构信息

Department of Developmental Medicine (Pediatrics), Osaka Utniversihv Graduate School of Medicine, Suita, Japan.

出版信息

Bone Marrow Transplant. 2000 Sep;26(6):681-3. doi: 10.1038/sj.bmt.1702584.

DOI:10.1038/sj.bmt.1702584

PMID:11041570

Abstract

We report a 5-year-old boy with juvenile myelomonocytic leukemia (JMML) which relapsed after an allogeneic bone marrow transplant who was successfully treated with interferon-alpha (IFN-alpha). One year after starting the therapy, he remains clinically well and in complete remission while continuing treatment with IFN-alpha and bestatin. Although the precise mechanism by which remission was induced is uncertain, a GVL effect combined with a direct antileukemia effect of IFN-alpha may be responsible. Further assessment of the role of IFN-alpha in relapsed JMLL patients is warranted.

摘要

我们报告了一名5岁患青少年型粒单核细胞白血病（JMML）的男孩，其在接受异基因骨髓移植后复发，经α干扰素（IFN-α）成功治疗。开始治疗一年后，他临床状况良好且处于完全缓解状态，同时继续接受IFN-α和贝司他汀治疗。虽然诱导缓解的确切机制尚不确定，但移植物抗白血病（GVL）效应与IFN-α的直接抗白血病效应可能起了作用。有必要进一步评估IFN-α在复发的JMLL患者中的作用。